[Stiff-Person Syndrome: Results of the First Nationwide Survey in Japan].

Q3 Medicine Brain and Nerve Pub Date : 2024-08-01 DOI:10.11477/mf.1416202713
Naoko Matsui, Keiko Tanaka, Yuishin Izumi
{"title":"[Stiff-Person Syndrome: Results of the First Nationwide Survey in Japan].","authors":"Naoko Matsui, Keiko Tanaka, Yuishin Izumi","doi":"10.11477/mf.1416202713","DOIUrl":null,"url":null,"abstract":"<p><p>Stiff-person syndrome (SPS) is a rare autoimmune neurological disorder characterized by progressive axial muscle stiffness, central nervous system hyperexcitability, and painful stimulus-sensitive muscle spasms. A nationwide survey performed in 2018 showed the estimated prevalence of SPS was 0.2 per 100,000 population. Most patients with SPS had antibodies against glutamic acid decarboxylase 65, followed by antibodies to the glycine receptor α-subunit. Usually, patients with SPS showed favorable outcomes; however, some studies have reported intractable SPS. Early diagnosis and aggressive immunotherapy are necessary for management of patients with SPS.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain and Nerve","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11477/mf.1416202713","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Stiff-person syndrome (SPS) is a rare autoimmune neurological disorder characterized by progressive axial muscle stiffness, central nervous system hyperexcitability, and painful stimulus-sensitive muscle spasms. A nationwide survey performed in 2018 showed the estimated prevalence of SPS was 0.2 per 100,000 population. Most patients with SPS had antibodies against glutamic acid decarboxylase 65, followed by antibodies to the glycine receptor α-subunit. Usually, patients with SPS showed favorable outcomes; however, some studies have reported intractable SPS. Early diagnosis and aggressive immunotherapy are necessary for management of patients with SPS.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[僵人综合症:日本首次全国性调查的结果]。
僵人综合征(SPS)是一种罕见的自身免疫性神经系统疾病,以进行性轴性肌肉僵硬、中枢神经系统过度兴奋和疼痛性刺激敏感性肌肉痉挛为特征。2018年进行的一项全国性调查显示,SPS的患病率估计为每10万人中有0.2人。大多数SPS患者具有谷氨酸脱羧酶65抗体,其次是甘氨酸受体α亚基抗体。通常,SPS 患者的预后良好;但也有一些研究报告称,SPS 难以治愈。早期诊断和积极的免疫疗法是治疗 SPS 患者的必要条件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Brain and Nerve
Brain and Nerve Medicine-Neurology (clinical)
自引率
0.00%
发文量
0
期刊最新文献
[A Case of the Anti-aquaporine-4 Antibody-negative Neuromyelitis Optica Spectrum Disorders Associated with Atopic Disease with High Concentration of Anti-IgE Autoantibody and HyperIgEemia]. [AMPA Receptors and Neuronal Plasticity]. [Anti-Amyloid Antibody Therapy for Alzheimer's Disease]. [B-cell Therapy for Multiple Sclerosis]. [Efficacy and Safety of Inebilizumab, an Anti-CD19 Monoclonal Antibody, for the Treatment of Neuromyelitis Optica Spectrum Disorder: Based on the N-MOmentum Trial].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1